When prescribing pregabalin for the treatment of neuropathic pain, prescribers should write the prescription with the brand name 'Lyrica', and not the generic name or the name of any other brand.
In the event of clinical contraindications or other considerations relating specifically to Lyrica (such as allergy to an excipient or unavailability of the branded product), neither Lyrica nor pregabalin should be prescribed.
Pregabalin should continue to be prescribed generically for all other indications.
This advice has been issued following the introduction of new pregabalin products, including Lecaent and Rewisca, with the expiry of patent protection for Lyrica in the treatment of epilepsy and generalised anxiety disorder. The patent remains in force for use of the product in neuropathic pain.